Stoke Therapeutics Inc. (STOK): 2Q26 EPS: Continued execution in Dravet ahead of Ph3 data in 3Q27

Research evidence excerpt

Stoke Therapeutics Inc. (STOK): 2Q26 EPS: Continued execution in Dravet ahead of Ph3 data in 3Q27

d other external clients of GS, depending on various factors including your

individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g.,

marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints.

As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request

that specific data underlying analysts’ fundamental analysis available on our internal client websites be delivered to them electronically through data

feeds or otherwise. No change to an analyst’s fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for

equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through

electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all

research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our

research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related

services) that may be available to you, please contact your GS representative or go to https://research.gs.com.